Literature DB >> 23486329

Multifocal extra-adrenal paraganglioma evaluated with different PET tracers: comparison between 18F-FDG, 18F-DOPA and 68Ga DOTANOC PET/CT.

Giorgio Treglia1, Giuseppe Cardillo, Antonella Stefanelli, Davide Di Franco, Gerard Ngome Enang, Alessandro Giordano, Vittoria Rufini.   

Abstract

A 40-year-old female patient with suspected multifocal extra-adrenal paraganglioma, on the basis of biochemical, genetic, and conventional imaging data, underwent 18F-FDG, 18F-DOPA and 68Ga DOTANOC PET/CT. FDOPA- and FDG-PET/CT detected a multifocal mediastinal and cervical paraganglioma. 68Ga-DOTANOC PET/CT detected 2 additional lesions compared to the other PET/CT methods. In our case, somatostatin receptor PET/CT with 68Ga-DOTANOC correctly assessed the extent of the disease in a patient with multifocal paraganglioma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486329     DOI: 10.1097/RLU.0b013e31827088d9

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?

Authors:  Giorgio Treglia; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12       Impact factor: 9.236

2.  A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.

Authors:  Alexander Kroiss; Daniel Putzer; Andreas Frech; Clemens Decristoforo; Christian Uprimny; Rudolf Wolfgang Gasser; Barry Lynn Shulkin; Christoph Url; Gerlig Widmann; Rupert Prommegger; Georg Mathias Sprinzl; Gustav Fraedrich; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

3.  Paraganglioma with highly malignant potential involving the rib - Case report and review of the literature.

Authors:  Yong Jia; Yi Yan; Miao Lu; Iain D C Kirkpatrick
Journal:  Radiol Case Rep       Date:  2021-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.